PATENT CLAIM ANALYSIS

Application Number: 15757696
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-06
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to the serine threonine kinase 32C (STK32C) gene relevant to breast cancer and a use thereof, and particularly, to a composition for the diagnosis, prevention, or treatment of breast cancer using the STK32C gene. In the present invention, changes in breast cancer cells according to STK32C gene expression differences were identified, and a breast cancer inhibitory effect according to the inhibition of expression of the STK32C gene and YB-1, which is a substrate protein, were newly verified, and thus target therapies are expected in treatment of breast cancer through more fundamental approaches.

Claim (Index 7):
A method of screening a breast cancer therapeutic material, the method comprising the following processes:\n a) treating serine threonine kinase 32C (STK32C)-expressing cells with a test material; b) measuring an expression or activity degree of STK32C in the cells; and c) selecting a test material that inhibits expression or activity of STK32C when compared to a control not treated with the test material, as a breast cancer therapeutic material.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 90.0
- Lexical Diversity: 1.81667
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13030860', '15617788', '13027038', '14798208', '15075373']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7144902041636519
- 35 USC 102 Novelty (BERT): 0.5224943996246773
- Combined Prediction Score: 0.6952906237097545
- Mean Citation Score: 298.24408
- Max Citation Score: 302.55
- Similarity Product: 212.79134945869447

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test